PFA
LTRN icon

Pathway Financial Advisors’s Lantern Pharma LTRN Stock Holding History

Pathway Financial Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,001
Closed -$220K – 175
2024
Q1 		$220K Sell
25,001
-3,500
-12% -$18.7K 0.06% 156
2023
Q4 		$122K Sell
28,501
-4,270
-13% -$15.1K 0.04% 158
2023
Q3 		$112K Buy
32,771
+18,770
+134% +$85.2K 0.04% 134
2023
Q2 		$79K Buy
+14,001
New +$72.3K 0.03% 133

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Pathway Financial Advisors's LTRN Position: Q2 2024 in Review

Pathway Financial Advisors sold out of Lantern Pharma (LTRN) in Q2 2024, closing a stake of 25,001 shares — an estimated $220K sold.

Pathway Financial Advisors first reported a position in LTRN in Q2 2023 and held it in 4 quarters. The position peaked at $220K in Q1 2024. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2024.

  • Pathway Financial Advisors reported no remaining Lantern Pharma position as of Q2 2024 after selling out during the quarter.
  • Pathway Financial Advisors sold 25,001 Lantern Pharma shares in Q2 2024, an estimated $220K.
  • Pathway Financial Advisors first reported a position in Lantern Pharma in Q2 2023 and held it in 4 quarters.
  • Pathway Financial Advisors's Lantern Pharma position peaked at $220K in Q1 2024.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2024.

Based on Pathway Financial Advisors's 13F filing for Q2 2024, filed 24 Jul 2024.